You are here
New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation
HCM Patients at Greater Risks of Atrial Fibrillation, Heart Failure and Increased Mortality
Younger Age of Diagnosis and Genetic Status Associated with Higher Rates of Long-term Complications and Early Death
SOUTH SAN FRANCISCO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) -- The Sarcomeric Human Cardiomyopathy Registry (SHaRe) and MyoKardia, Inc. (Nasdaq: MYOK) announced today the publication of results from a multicenter, international, longitudinal study of data from nearly 4,600 patients with hypertrophic cardiomyopathy (HCM), the largest comprehensive HCM cohort assembled to date. Hypertrophic cardiomyopathy is a chronic and progressive disease characterized by increased thickening of the heart muscle. Analyses of SHaRe data revealed that HCM patients are at substantially elevated risks of long-term complications and comorbidities, such as atrial fibrillation and heart failure. HCM patients also have significantly higher mortality rates compared to that of the general U.S. population. Further, patients with genetic HCM exhibited clinical disease at younger ages and were more likely to experience HCM-related complications and early death than patients with non-genetic HCM. The article, “Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)” will be published in an upcoming print edition of Circulation, the peer-reviewed journal of the American Heart Association. A copy of the manuscript is now available via the following link: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.033200.
“These data provide a comprehensive and far-reaching look at the impact of HCM on patients’ lives and importantly change our understanding of their risks over time,” said Carolyn Ho, M.D., Associate Professor of Medicine at Harvard Medical School, Medical Director of the Cardiovascular Genetics Center at Brigham and Women’s Hospital and lead author of the SHaRe paper. “The cumulative burden and progressive nature of HCM emphasizes that patients require careful long-term follow-up and underscores the need to develop disease-modifying therapies that may avert the onset of serious comorbidities.”
Researchers from eight high-volume HCM centers associated with SHaRe analyzed clinical information collected from 4,591 patients diagnosed with HCM to understand the cumulative burden of disease over a lifetime. The data set reflects more than 24,000 patient-years. Data from SHaRe demonstrate that:
- The burden of disease and complications increased progressively over time for HCM patients, with most HCM-related complications occurring later in life between the ages of 50-70 years.
- The late onset of severe comorbidities implies that adverse remodeling of the HCM heart is occurring throughout life.
- The most frequently reported comorbidities were heart failure and atrial fibrillation.
- Mortality among HCM patients was shown to be approximately three-fold higher than the United States general population at similar ages (per the Centers for Disease Control database). Compared to the U.S. general population, mortality was four times higher among young HCM patients (ages 20-29 years).
Additional analyses were performed examining the impact of sarcomeric mutations and age of diagnosis on disease experience. Genetic information was available for 2,763 HCM patients in the registry and 46 percent of these patients possessed a sarcomeric mutation presumed to cause their disease.
- In patients with sarcomere mutations, the median age of diagnosis was 37.5 years, compared to 51.1 years for patients without a sarcomere mutation.
- Patients with sarcomeric mutations experienced earlier onset of HCM-related complications and the cumulative burden of disease was shown to be substantial.
- Younger age at the time of HCM diagnosis was associated with increased cumulative incidence of adverse events: HCM patients under 40 years old at the time of diagnosis had a 77 percent cumulative incidence of cardiac arrest, defibrillator or left-ventricular assist device (LVAD) implantation, Class III or IV heart failure symptoms, heart transplantation, atrial fibrillation, stroke or death by age 60. In contrast, patients diagnosed with HCM after the age of 60 years had a 32 percent cumulative incidence of such complications by age 70 years.
“We are greatly indebted to the SHaRe researchers who continue to contribute to this remarkable collective effort to transform our understanding of the HCM patient journey. The data published in Circulation provide seminal insights into the burden of disease on HCM patients, underscoring the profound risks associated with HCM over time and the urgent need for therapies that can potentially alter the course of disease,” said Marc Semigran, M.D., Chief Medical Officer of MyoKardia. “MyoKardia’s goal supporting SHaRe is to obtain meaningful longitudinal and centralized data to better understand the risks associated with cardiomyopathy and the course of disease progression. As we gain a greater understanding of the factors driving HCM, we will be able to develop better treatments to potentially alter the progression of the disease to prevent late-stage manifestations of HCM’s progression, such as heart failure and atrial fibrillation.”
The SHaRe centers contributing data to this study include Brigham and Women’s Hospital, Boston; University of Michigan Medical Center; Stanford University Medical Center; Boston Children’s Hospital; Yale-New Haven Hospital; Florence Centre for Cardiomyopathies, Italy; Erasmus University Medical Center, Netherlands; and InCOR, Sao Paulo, Brazil.
The Sarcomeric Human Cardiomyopathy Registry (SHaRe) was formed in 2014 by MyoKardia, Inc. in collaboration with several world-leading cardiovascular centers with the goal of advancing the understanding of hypertrophic cardiomyopathy (HCM). The registry collects and serves as a repository of clinical and laboratory data on individuals and families with genetic heart disease. Since its formation, SHaRe has grown into the largest international database of clinical information on HCM patients with de-identified data on more than 8,000 subjects worldwide.
About MyoKardia, Inc.
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of two of the most prevalent forms of heritable cardiomyopathy – hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin intended to reduce hypercontractility. Mavacamten is being studied in a pivotal Phase 3 clinical trial, known as EXPLORER-HCM, in patients with symptomatic, obstructive HCM. MyoKardia is also developing mavacamten in a second indication, non-obstructive HCM, in the Phase 2 MAVERICK-HCM clinical trial. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1b study in DCM patients. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.
CONTACT: Contacts: Michelle Corral Corporate Communications & Investor Relations MyoKardia, Inc. 650-351-4690 email@example.com Hannah Deresiewicz (Investors) Stern Investor Relations, Inc. 212-362-1200 firstname.lastname@example.org Steven Cooper (Media) Edelman 415-486-3264 email@example.com